DESIGN AND DEVELOPMENT OF MEDICATED CHEWING GUM FOR MANAGEMENT OF DEPRESSION
AbstractThe objective of research work is to formulate a venlafaxine HCl containing medicated chewing gum that has greater bioavailability and compliances than conventional treatment strategies. The four different formulations were prepared after some trial batches, containing different concentrations of the gum base and sucrose (MCG- I- MCG- IV). These batches were optimized on basis of softness and sweetness. Batch MCG- II was found to be optimized containing 60% gum base and 15% of sucrose. Further batches were characterized on basis of Physical characterization, texture analysis, drug content and in-vitro drug release. All batches show good color, softness, and taste. Drug content was found out in a range of 98.43- 99.24%. The in-vitro drug release data revealed that MCG- II shows better drug release than other formulations. Medicated chewing gum can be a better choice for the treatment of depression in the coming years, which may provide several benefits to patient.
Download